Stocks · News reference

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Jul 15, 2026, 5:47 PMVandana Singh

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 8:54 PMBenzinga Newsdesk
Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate
Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.65) by 10.77 percent. This is a 97.6 percent increase over losses of $(24.19) per share from the
MANE
SEC EDGARAug 11, 2026, 12:15 PMSEC EDGAR
8-K filing — Veradermics, Inc (MANE)
Filed: 2026-08-11 AccNo: 0001827635-26-000028 Size: 641 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MANE
BenzingaJul 17, 2026, 5:52 PMBenzinga Newsdesk
Veradermics shares are trading higher after the company announced the presentation of data from the Phase 2/3 Study ‘302’ of VDPHL01 in male patients with mild-to-moderate pattern hair loss.
MANE
BenzingaJul 17, 2026, 11:32 AMBenzinga Newsdesk
Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the
MANE